FLINT, Mich., Aug. 8, 2019 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), is pleased to announce an
exclusive agreement between Diplomat and Allergy Partners, P.A., to
manage in-office and in-home delivery and administration of
infusion drugs and biologics. The agreement will cover treatments
for primary immunodeficiency, alpha-1 antitrypsin deficiency,
hereditary angioedema, and more.
Allergy Partners is the nation's largest independent,
single-specialty practice for allergic disease, asthma, and
immunology. Their fast-growing national network consists of 161
providers across 128 locations and 20 states.
The five-year agreement, which includes renewal provisions,
should allow both organizations to leverage their consolidated
purchase volume within the growing marketplace for allergy and
immunology biologics. It also creates a unique and preeminent
treatment platform for patients that supports both companies' core
value of putting patients first. Under this management agreement,
Diplomat will provide clinical oversight and staffing, nursing
services, information technology, materials management,
reimbursement, and certain finance and accounting services on
behalf of Allergy Partners' 128 practice locations.
The agreement includes the integration of both parties'
information technology platforms to support close care coordination
between Allergy Partners' physicians and the pharmacy and nursing
service teams that Diplomat will be managing.
"Diplomat's significant experience and expertise in managing
patients in the allergy and immunology space puts us in a unique
position to complement the mission of Allergy Partners," said
Brian Griffin, chairman and CEO of
Diplomat. "This innovative agreement will support Diplomat's growth
in infusion therapies, and we are looking forward to collaborating
with Allergy Partners."
"Allergy Partners is excited for this partnership with
Diplomat," said David A. Brown,
M.D., president and CEO of Allergy Partners. "This relationship
between a specialized practice and an infusion service provider is
one of the first of its kind, a natural complementary relationship.
It furthers our goal of being the leader in the development of
high-quality care for patients with allergic and immunologic
disorders."
About Allergy Partners
Founded in 1977, Allergy Partners was established in
Asheville, North Carolina, by J.
Spencer Atwater Jr., M.D.,
specializing in the practice of allergy, asthma, and immunology. In
1987, David A. Brown joined the
practice to fill the area's growing need for high quality medical
care. In the early 1990s, the practice began to pursue a national
growth strategy that has continued to this day. To learn more about
Allergy Partners, visit allergypartners.com.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy and infusion services. Diplomat
helps people with complex and chronic health conditions in all 50
states, partnering with payers, providers, hospitals,
manufacturers, and more. Rooted in this patient care expertise,
Diplomat also serves payers through CastiaRx, a leading specialty
benefit manager, and offers tailored solutions for healthcare
innovators through EnvoyHealth. Diplomat opened its doors in 1975
as a neighborhood pharmacy with one essential tenet: "Take good
care of patients and the rest falls into place." Today, that
tradition continues — always focused on improving patient care. For
more information, visit diplomat.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance, and may include Diplomat's
expectations regarding market share, the expected benefits and
performance of growth strategies, specifically for infusion
therapies, leveraging purchase volumes for allergy and immunology
biologics (and any implied financial impact), our ability to
provide pharmacy management services (and any implied financial
impact), and integrating information technology platforms and
coordinating care between physicians and Diplomat. The
forward-looking statements contained in this press release are
based on management's good-faith belief and reasonable judgment
based on current information. These statements are qualified
by important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. These risks and uncertainties include: the
volume of management services utilized; our ability to adapt to
changes or trends within the specialty pharmacy industry; a
significant increase in competition from a variety of companies in
the health care industry; our ability to leverage purchase volumes
for allergy and immunology biologics; supply disruption of
specialty drugs; bad publicity about, or market withdrawal of,
specialty drugs; disruption in our operations as we integrate
information technology and operational platforms
to coordinating care between physicians and Diplomat;
complying with complex and evolving requirements and changes in
state and federal government regulations, including Medicare and
Medicaid; current or proposed legislative and regulatory policies
designed to manage healthcare costs or alter healthcare financing
practices; investments in new business strategies and initiatives,
including with respect to data and analytics capabilities, could
disrupt our ongoing business and present risks not originally
contemplated; and the additional factors set forth in "Risk
Factors" in Diplomat's most recent Annual Report on
Form 10-K and in subsequent reports filed with or
furnished to the Securities and Exchange Commission. Except as
may be required by any applicable laws, Diplomat assumes no
obligation to publicly update such forward-looking statements,
which are made as of the date hereof or the earlier date specified
herein, whether as a result of new information, future
developments, or otherwise.
CONTACT:
Terri Anne
Powers, Vice President of Investor Relations
312.889.5244 | tpowers@diplomat.is
Jennifer Pavlovich, Corporate
Communications Manager
810.768.9282 | press@diplomat.is
View original content to download
multimedia:http://www.prnewswire.com/news-releases/diplomat-signs-exclusive-practice-based-infusion-agreement-with-allergy-partners-300899191.html
SOURCE Diplomat Pharmacy, Inc.